AR006281A1 - Utilizacion de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinometanol o sus sales de adicion de acidos farmaceuticamenteaceptables en el tratamineto de trastornos depresivos y trastornos bipolares - Google Patents

Utilizacion de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinometanol o sus sales de adicion de acidos farmaceuticamenteaceptables en el tratamineto de trastornos depresivos y trastornos bipolares

Info

Publication number
AR006281A1
AR006281A1 ARP970101085A ARP970101085A AR006281A1 AR 006281 A1 AR006281 A1 AR 006281A1 AR P970101085 A ARP970101085 A AR P970101085A AR P970101085 A ARP970101085 A AR P970101085A AR 006281 A1 AR006281 A1 AR 006281A1
Authority
AR
Argentina
Prior art keywords
depressive
alpha
treatment
piperidinometanol
dimetoxifenil
Prior art date
Application number
ARP970101085A
Other languages
English (en)
Original Assignee
Hoechst Marion Roussell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussell Inc filed Critical Hoechst Marion Roussell Inc
Publication of AR006281A1 publication Critical patent/AR006281A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

Se refiere a la utilización de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4- fluorofenil)etil]-4-piperidinometanol en la preparación de una composiciónfarmacéutica para el tratamiento de trastornos depresivos y trastornos bipolares.
ARP970101085A 1996-03-21 1997-03-19 Utilizacion de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinometanol o sus sales de adicion de acidos farmaceuticamenteaceptables en el tratamineto de trastornos depresivos y trastornos bipolares AR006281A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96400591A EP0796619A1 (en) 1996-03-21 1996-03-21 Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders

Publications (1)

Publication Number Publication Date
AR006281A1 true AR006281A1 (es) 1999-08-11

Family

ID=8225234

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101085A AR006281A1 (es) 1996-03-21 1997-03-19 Utilizacion de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinometanol o sus sales de adicion de acidos farmaceuticamenteaceptables en el tratamineto de trastornos depresivos y trastornos bipolares

Country Status (23)

Country Link
US (2) US6022877A (es)
EP (2) EP0796619A1 (es)
JP (1) JP4165906B2 (es)
KR (1) KR100423018B1 (es)
CN (1) CN1114406C (es)
AR (1) AR006281A1 (es)
AT (1) ATE219672T1 (es)
AU (1) AU704435B2 (es)
BR (1) BR9708109A (es)
CA (1) CA2250077C (es)
DE (1) DE69713571T2 (es)
DK (1) DK0888114T3 (es)
ES (1) ES2175356T3 (es)
HK (1) HK1019702A1 (es)
HU (1) HU226675B1 (es)
IL (1) IL126022A (es)
NO (2) NO316788B1 (es)
NZ (1) NZ331448A (es)
PT (1) PT888114E (es)
SI (1) SI0888114T1 (es)
TW (1) TW517048B (es)
WO (1) WO1997034603A1 (es)
ZA (1) ZA972345B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
TWI249526B (en) * 1998-03-13 2006-02-21 Aventis Pharma Inc Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US6713627B2 (en) 1998-03-13 2004-03-30 Aventis Pharmaceuticals Inc. Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US6277864B1 (en) 1998-08-28 2001-08-21 Aventis Pharmaceuticals Inc. Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders
HUP0202145A3 (en) * 1998-08-28 2003-02-28 Aventis Pharmaceuticals Inc Br The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders
US6939879B2 (en) 1998-08-28 2005-09-06 Aventis Pharmaceuticals Inc. Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia
US20020099076A1 (en) 2000-05-25 2002-07-25 Richard Scheyer D. Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
US20020161026A1 (en) * 2000-11-07 2002-10-31 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
ATE305467T1 (de) * 2001-01-31 2005-10-15 Pfizer Prod Inc Als inhibitoren von pde4-isozymen geeignete etherderivate
WO2009152647A1 (zh) * 2008-06-20 2009-12-23 江苏恩华药业股份有限公司 芳烷基哌啶衍生物及其在制备镇痛、镇静药物中的应用
US8188119B2 (en) * 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169096A (en) * 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
US4912117A (en) * 1985-07-02 1990-03-27 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds
US4783471A (en) * 1985-07-02 1988-11-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine methanol derivatives and the uses thereof
US5021428A (en) * 1985-07-02 1991-06-04 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds for the prophylactic treatment of migraine
US4762842A (en) * 1985-10-01 1988-08-09 Eli Lilly And Company Selective method for blocking 5HT2 receptors
US4877798A (en) * 1987-11-23 1989-10-31 Merrell Dow Pharmaceuticals Inc. Treatment of fibromyalgia
JPH02138214A (ja) * 1987-12-10 1990-05-28 Merrell Dow Pharmaceut Inc 不安を治療する方法
EP0325063B1 (en) * 1988-01-21 1994-03-09 Merrell Dow Pharmaceuticals Inc. Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
US5064838A (en) * 1988-01-21 1991-11-12 Merrell Dow Pharmaceuticals 1,4-disubstituted-piperidinyl compounds as pain relievers
ZA891901B (en) * 1988-03-17 1989-11-29 Merrell Dow Pharma Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy
US4902691A (en) * 1988-12-19 1990-02-20 Eli Lilly And Company Heteroalkylamides of (8-β)-1-alkyl-6-(substituted)ergolines useful for blocking 5HT2 receptors
US5106855A (en) * 1989-12-20 1992-04-21 Merrell Dow Pharmaceuticals Inc. Method for the treatment of glaucoma
AU652759B2 (en) * 1990-06-01 1994-09-08 Aventisub Ii Inc. (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
IL125031A0 (en) * 1995-12-22 1999-01-26 Lilly Co Eli Method for treating depression
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders

Also Published As

Publication number Publication date
IL126022A (en) 2003-11-23
US6380216B1 (en) 2002-04-30
HUP9902135A3 (en) 2001-05-28
PT888114E (pt) 2002-11-29
CN1213968A (zh) 1999-04-14
DK0888114T3 (da) 2002-10-07
DE69713571T2 (de) 2003-02-20
HU226675B1 (en) 2009-06-29
NZ331448A (en) 2000-06-23
ZA972345B (en) 1997-09-25
EP0796619A1 (en) 1997-09-24
NO984348L (no) 1998-09-18
HUP9902135A2 (hu) 1999-11-29
KR20000064711A (ko) 2000-11-06
WO1997034603A1 (en) 1997-09-25
JP2000506887A (ja) 2000-06-06
SI0888114T1 (en) 2002-10-31
EP0888114A1 (en) 1999-01-07
KR100423018B1 (ko) 2004-05-17
ATE219672T1 (de) 2002-07-15
AU704435B2 (en) 1999-04-22
NO316788B1 (no) 2004-05-10
IL126022A0 (en) 1999-05-09
NO984348D0 (no) 1998-09-18
CA2250077A1 (en) 1997-09-25
EP0888114B1 (en) 2002-06-26
AU1963197A (en) 1997-10-10
JP4165906B2 (ja) 2008-10-15
CN1114406C (zh) 2003-07-16
HK1019702A1 (en) 2000-02-25
NO20033184L (no) 1998-09-18
TW517048B (en) 2003-01-11
BR9708109A (pt) 1999-07-27
ES2175356T3 (es) 2002-11-16
US6022877A (en) 2000-02-08
NO20033184D0 (no) 2003-07-11
CA2250077C (en) 2003-10-07
DE69713571D1 (de) 2002-08-01

Similar Documents

Publication Publication Date Title
FI925342A (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
ITRM920155A1 (it) Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
AR018197A1 (es) Compuestos de piperidina, un procedimiento para su preparacion, una composicion y uso del mismo para la preparacion de un medicamento
ES2077199T3 (es) Nuevas piperacinas 1,4-disustituidas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
SE9900961D0 (sv) Novel compounds
AR006281A1 (es) Utilizacion de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinometanol o sus sales de adicion de acidos farmaceuticamenteaceptables en el tratamineto de trastornos depresivos y trastornos bipolares
SE9802208D0 (sv) Novel compounds
DE69923336D1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
ES2054718T3 (es) El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
FI963394A0 (fi) Yskää vastustava koostumus, joka sisältää yskää vastustavaa ainetta ja bentsydamiinia
SE0001916D0 (sv) Novel formulation
SE9802209D0 (sv) Novel compounds
DE69813263D1 (de) Hydrazono-benzazulen-derivate, pharmazeutische zusammensetzungen und zwischenprodukte
AR023452A1 (es) Utilizacion del osanetant para preparacion de medicamentos utiles en el tratamiento de los trastornos del humor
NO20091111L (no) Anvendelse av R(+)-alfa-(2,3-dimetoksyfenyl)-l-[2-(4-fluorfenyl)etyl]-4-piperidin-metanol for behandling av sovnforstyrrelser
EE200100219A (et) (+)-alfa-(2,3-dimetoksüfenüül)-1-[2-(4-fluorofenüül)etüül]-4-piperidiinmetanooli estrid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
ATE397447T1 (de) Feste paroxetin enthaltende zubereitungen
TW200420560A (en) Crystalline form
AR003117A1 (es) El uso de derivado de aminotetralina para la preparacion de composiciones farmaceuticas para la terapia de enfermedades cardiovasculares y dichascomposiciones farmaceuticas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure